AI intervention in Epilepsy Diagnosis and Treatment

By Sumona Bose

February 15, 2024

Introduction

Epilepsy, a neurological disorder characterised by recurrent seizures, affects millions of people worldwide. The ability to accurately detect and predict seizures is crucial for effective management and treatment of this condition. In recent years, artificial intelligence (AI) and machine learning have emerged as powerful tools in the field of epilepsy research, offering new insights and possibilities for improving patient outcomes. AI intervention in epilepsy diagnosis and treatment remain a sought after matter of investigation.

Examining Epileptic Brain States

Epileptic brain dynamics can be divided into four states: inter-ictal(period between seizures, i.e., a normal state of patients), pre-ictal (period immediately before the seizure onset), ictal (period during seizure), and post-ictal (period immediately after the seizure). Understanding the characteristics of each state and the transitions between them is essential for unravelling the mechanisms underlying epilepsy and developing targeted interventions. Traditional studies have focused on seizure detection and prediction, aiming to identify the onset of seizures and forecast their occurrence in advance.

Many recent studies have focused on implementing the computational predictive models to localize SOZs or judge epileptic brain states, such as pre-ictal and ictal onset, by employing traditional machine learning algorithms or deep learning algorithms based on scalp EEG and/or iEEG data recorded from epilepsy patients. Compared to the traditional machine learning approach, which consists of two step processes of manually extracting the features of the data and training the machine by applying the features as inputs, deep learning approach automatically figures out the discriminative features from data and learns them. SOZ, seizure onset zones; EEG, electroencephalogram; iEEG, intracranial EEG.

AI in Seizure Detection

Numerous studies have demonstrated the effectiveness of computational models in seizure detection. These models, trained using machine learning algorithms, can analyse data from scalp electroencephalography (EEG) or intracranial EEG recordings to identify seizure patterns. For instance, Emami and colleagues developed a convolutional neural network (CNN)-based model that automatically learned the characteristics of seizure and non-seizure states. The model achieved an average positive rate of 74% for seizure onset detection when the entire EEG time series was input sequentially by one second. This breakthrough paves the way for on-demand stimulation therapies or acute drug treatments, providing timely interventions for patients.

AI in Seizure Prediction

Predicting seizures before their onset is another critical aspect of epilepsy management. Computational models trained on time and/or frequency domain features observed in the pre-ictal state have shown promising results in predicting seizures several minutes before they occur. These models, employing supervised learning methods and various algorithms such as support vector machines (SVM) and deep learning techniques like recurrent neural networks (RNN), have achieved sensitivities of 80-90%. Importantly, recent studies have focused on developing patient-specific models based on individual data, recognizing the unique signal patterns of each patient. This personalised approach holds great potential for clinical applications, enabling tailored treatment plans and interventions.

In conclusion, the integration of AI and machine learning in epilepsy research has shown promise in the field by enabling accurate seizure detection and prediction. These computational models have the potential to improve patient outcomes by providing timely interventions and personalised treatment plans. As technology continues to advance, AI will play an increasingly vital role in transforming epilepsy diagnosis and treatment.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.